FDA Concerned with H. Lundbeck A/S Drug Serdolect Death Risk

Reuters - U.S. regulators remain concerned about a possible risk of sudden cardiac death with H Lundbeck A/S's (LUN.CO) proposed schizophrenia drug Serdolect, documents released on Friday said.